 |
 |
 |
 |
 |
 |
|
| Sign up on our mailing list by emailing us at: subscribe@QuatRx.com |
 |
 |
QUATRX PHARMACEUTICALS ANNOUNCES NEW MANAGEMENT APPOINTMENTS
Rochelle Hanley, M.D., joins QuatRx as chief medical officer
[Released September 19, 2006]
ANN ARBOR, MI—QuatRx Pharmaceuticals, a biopharmaceutical company focused on research and development of therapeutic compounds for the treatment of major endocrine, metabolic and cardiovascular diseases, today announced the appointment of Rochelle Hanley, M.D., as chief medical officer. Dr. Hanley will oversee clinical development of QuatRx’s product pipeline. Prior to joining QuatRx, Dr. Hanley was vice president, clinical R&D site head of Pfizer’s Michigan Laboratories, where she oversaw the clinical operations of Pfizer’s Michigan research and development facility. Dr. Hanley has extensive experience managing clinical development, especially in metabolic disorders and cardiovascular disease. In her career, Dr. Hanley has also held clinical development management roles at both Glaxo Wellcome and Parke-Davis Pharmaceutical Research.
Other Management Changes
Along with Dr. Hanley’s appointment, Randy Whitcomb, M.D., a founder of QuatRx and its chief medical officer since inception, has been appointed senior clinical research fellow. Dr. Whitcomb will advise on research and development matters and will join the Company’s Scientific Advisory Board.
Christopher Nicholas has been promoted to chief operating officer. Mr. Nicholas is a founder of QuatRx and has served as its chief business officer since inception. Mr. Nicholas has more than 25 years of global pharmaceutical marketing, business development and general management experience at companies including Bayer, Hoechst/Roussel and Parke-Davis.
"Dr. Hanley and Dr. Whitcomb together provide unparalleled expertise which is closely aligned with our therapeutic focus, and when combined with our new management structure, position us well for the effective management of our growing and advancing portfolio of clinical stage programs, including Ophena™, fispemifene and Asord™," said Robert L. Zerbe, M.D., president and chief executive officer of QuatRx Pharmaceuticals.
About QuatRx
QuatRx Pharmaceuticals Company is focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas. QuatRx currently has four product candidates in clinical development. QuatRx’s two lead compounds treat hormone deficiencies that result from aging in women and men. Ophena™ is in Phase III development initially for the treatment of vaginal atrophy, a common problem associated with estrogen deficiency in post-menopausal women. Fispemifene, a treatment for testosterone deficiency, is in Phase II clinical testing. QuatRx also has QRX-431, a product candidate for the treatment of elevated cholesterol levels, and Asord™, a topical product candidate for the treatment of mild to moderate psoriasis, which has completed a Phase IIb clinical trial.
|
Terms of Use